Taysha Gene Therapies (TSHA) EPS (Weighted Average and Diluted) (2022 - 2025)
Taysha Gene Therapies (TSHA) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.08 as the latest value for Q4 2025.
- Quarterly EPS (Weighted Average and Diluted) fell 14.29% to -$0.08 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.34 through Dec 2025, up 5.56% year-over-year, with the annual reading at -$0.34 for FY2025, 5.56% up from the prior year.
- EPS (Weighted Average and Diluted) hit -$0.08 in Q4 2025 for Taysha Gene Therapies, up from -$0.09 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.92 in Q4 2023 to a low of -$1.32 in Q1 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.32 across 4 years, with a median of -$0.1 in 2024.
- Biggest five-year swings in EPS (Weighted Average and Diluted): surged 192.93% in 2023 and later crashed 107.61% in 2024.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.99 in 2022, then soared by 192.93% to $0.92 in 2023, then plummeted by 107.61% to -$0.07 in 2024, then dropped by 14.29% to -$0.08 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for TSHA at -$0.08 in Q4 2025, -$0.09 in Q3 2025, and -$0.09 in Q2 2025.